2014
DOI: 10.1016/j.nucmedbio.2014.07.003
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of methods for evaluating radiolabelled Annexin A5 uptake in pre-clinical PET oncological studies

Abstract: These results provide additional support for the recognition that more detailed investigations on the effects of the tumour microenvironment on the targeting capability of imaging radiopharmaceuticals are needed.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
3
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 44 publications
1
3
0
Order By: Relevance
“…Our findings support the reliable use of both graphical analysis methods in addition to the standard 1TC model for tracer kinetic analysis of V T . These findings agree with previous studies using other PET tracers that compared various graphical models, including the Logan method, finding the results to be in agreement with standard compartment models, but computationally simpler, and potentially more robust [ 24 – 27 ].…”
Section: Discussionsupporting
confidence: 91%
“…Our findings support the reliable use of both graphical analysis methods in addition to the standard 1TC model for tracer kinetic analysis of V T . These findings agree with previous studies using other PET tracers that compared various graphical models, including the Logan method, finding the results to be in agreement with standard compartment models, but computationally simpler, and potentially more robust [ 24 – 27 ].…”
Section: Discussionsupporting
confidence: 91%
“…5), with a modest 40% increase in radioactivity accumulation following drug treatment detectable by average counts in excised tumors. Non-specific tumor retention of Annexin V in the vascular space has recently been attributed to changes in enhanced permeability and retention (EPR) effects at baseline and post therapy (39). Despite advances in both site-specific and PET labeling strategies little has been achieved to improve the in vivo profile and tumor binding of this radiotracer (40).…”
Section: Discussionmentioning
confidence: 99%
“…6d – f ) by subtracting the TACs of the non-targeting ligand from that of the targeting to give a measure of the specific uptake. Compartmental modeling can be used to further quantify the binding and non-specific uptakes (e.g., [ 29 , 30 ] reviewed in [ 7 ]). However, TACs from several of these studies (e.g., Figs.…”
Section: Discussionmentioning
confidence: 99%